Available evidence suggests that medication used for the symptomatic improvement of parkinsonism in people with PD, especially catechol-O methyltransferase inhibitors, may also interfere with the composition of the gut microbiota [19,73]. This evidence concerns the gene COMT and Parkinson disease.